Wegovy vs Zepbound
Wegovy vs Zepbound compared for weight-management: evidence, dosing and cost.
Direct answer
The better choice depends on indication, route, evidence, contraindications and patient preference. semaglutide and tirzepatide should not be treated as interchangeable simply because both are discussed in weight-management care.
Wegovy vs Zepbound compared for weight-management: evidence, dosing and cost.
Clinical comparison
| Question | Wegovy | Zepbound |
|---|---|---|
| Regulatory status | Semaglutide is FDA approved in several products and indications, including Wegovy for chronic weight management. Compounded semaglutide is not an FDA-approved finished product, and semaglutide sodium or acetate salts are not the active ingredient used in approved products. | Tirzepatide is FDA approved as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes. Compounded tirzepatide is not an FDA-approved finished product. |
| Mechanism | Semaglutide is a GLP-1 receptor agonist that influences appetite and satiety, slows gastric emptying and improves glucose-dependent insulin secretion. | Tirzepatide activates both GIP and GLP-1 receptors. The combined incretin effect reduces appetite and energy intake, slows gastric emptying most strongly during initiation, and improves glucose-dependent insulin signaling. |
| Best evidence | In STEP 1, adults without diabetes receiving semaglutide 2.4 mg weekly had a mean weight change of −14.9% at 68 weeks versus −2.4% with placebo, alongside lifestyle intervention. Results apply to the studied product, titration and population; they do not validate every compounded concentration or lower-dose program. | In SURMOUNT-1, adults without diabetes receiving 5, 10 or 15 mg weekly achieved mean weight changes of about −15.0%, −19.5% and −20.9% at 72 weeks, versus −3.1% with placebo. In the 751-person SURMOUNT-5 head-to-head trial, tirzepatide produced −20.2% mean weight change versus −13.7% with semaglutide at 72 weeks. |
| Dose context | Wegovy injection begins at 0.25 mg weekly and generally increases every four weeks through 0.5, 1.0 and 1.7 mg to a maintenance dose of 1.7 or 2.4 mg weekly. Product-specific labeling controls; compounded units cannot be inferred from milligrams without the exact concentration. | Zepbound starts at 2.5 mg weekly for four weeks, then 5 mg weekly. Increases are made in 2.5 mg steps after at least four weeks based on response and tolerability; approved maintenance doses are 5, 10 or 15 mg weekly. |
| Key safety context | Common adverse effects include nausea, diarrhea, vomiting, constipation and abdominal pain. FDA labeling addresses thyroid C-cell tumor risk observed in rodents, pancreatitis, gallbladder disease, kidney injury related to dehydration, diabetic retinopathy complications in some patients and hypoglycemia when combined with insulin or sulfonylureas. | Common adverse effects are gastrointestinal—nausea, diarrhea, vomiting, constipation and abdominal symptoms. Labeling includes a boxed warning regarding thyroid C-cell tumors observed in rodents and cautions involving pancreatitis, gallbladder disease, kidney injury related to dehydration, hypoglycemia with certain diabetes drugs and severe gastrointestinal disease. |
Decision matrix
| Priority | When Wegovy may fit | When Zepbound may fit |
|---|---|---|
| Lowest complete recurring cost | Choose only if the normalized total is lower and the term fits | Choose only if the normalized total is lower and the term fits |
| FDA-approved product | Confirm the exact approved brand and indication | Confirm the exact approved brand and indication |
| Compounded customization | Requires patient-specific clinical rationale and a verified pharmacy | Requires patient-specific clinical rationale and a verified pharmacy |
| Live clinical access | Review visit format, response time and escalation | Review visit format, response time and escalation |
| Flexibility | Compare cancellation and prepayment terms | Compare cancellation and prepayment terms |
What marketing comparisons usually omit
A “from” price often omits the renewal rate, membership, dose tier, shipping or commitment. A provider count does not show whether every option is actually available in the patient’s state. A named pharmacy does not prove which legal entity will dispense a particular prescription. A high average review score does not substitute for medication-specific clinical evidence.
Frequently asked questions
Which is cheaper: Wegovy or Zepbound?
Use the normalized table rather than a headline. A first month, starter dose, medication-only amount or long-term equivalent is not a like-for-like monthly program.
Which has better clinical evidence?
For medicines, evidence follows the exact FDA-approved product and regimen. For providers, clinical quality depends on screening, prescriber accountability, follow-up and the dispensed product—not the brand name of the website.
What is the most important comparison question?
Confirm the exact medication and dose, total recurring cost, required commitment, clinician, assigned pharmacy, follow-up access and cancellation terms.
Can one provider pay for the winning position?
No. Providers cannot purchase inclusion, placement, a higher score or an editorial award.
How to make the final choice
Write the two options in a single-row worksheet using the same treatment month. Record exact medication, route, prescribed dose, recurring program fee, required membership, shipping, laboratory charges, commitment, assigned pharmacy and expected follow-up. A difference that disappears after adding a membership is not a price advantage.
Then separate preferences from safety requirements. Convenience preferences include injection versus tablet, live versus asynchronous communication and coaching style. Safety requirements include contraindication review, accurate concentration instructions, licensed prescribing, emergency limitations and continuity when adverse effects or supply problems occur.
The comparison is time sensitive. A manufacturer can change an offer, a provider can change pharmacies and a formulary can change coverage. Recheck material terms immediately before enrollment rather than relying on a saved ranking position.